Johns Hopkins Medicine and biotech company Orgenesis are partnering to launch the Maryland Center for Cell Therapy Manufacturing, supported by a $5 million matching grant from the State of Maryland.
The facility will close the loop on the biotech ecosystem in Maryland while allowing for lab and patient trials to be done in Baltimore instead of outsourced to another city, like Boston or Philadelphia, which would keep dollars flowing inside the city instead of leaving it.
The dream is to make Baltimore a life sciences hub akin to Gaithersburg or Frederick, and allow the city to reap the benefits of the vaunted “DNA Valley” along the I-270 corridor. Luke Thorstenson, director of business development at Orgenesis and former director of corporate partnerships at John Hopkins, is working to make that dream a reality.
READ FULL ARTICLE HERE
